Nautilus Secures Baylor College of Medicine as First Voyager Platform Early Access Customer
Summary
Nautilus Biotechnology announced Baylor College of Medicine as the first customer for its Voyager Platform's Early Access Program. Baylor will utilize the platform for an NIH-funded study focused on developing a computational multi-omics toolkit for high-resolution cancer isoform analysis. This news follows the company's recent 10-K filing on February 27, 2026, which initially announced the launch of the Early Access Program. Securing a reputable institution like Baylor as the initial customer for its flagship platform is a significant validation for Nautilus, a development-stage company, marking a crucial step in the commercialization of its novel single-molecule proteome analysis technology. The NIH funding for Baylor's project further enhances the scientific credibility and potential impact of the Voyager Platform. Traders will be watching for additional customer announcements and updates on the Baylor collaboration as indicators of market acceptance and future revenue potential.
At the time of this announcement, NAUT was trading at $2.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $335.4M. The 52-week trading range was $0.62 to $3.08. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.